Lipella Pharmaceuticals Ownership 2024 | Who Owns Lipella Pharmaceuticals Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

1.31%

Insider Ownership

35.49%

Retail Ownership

63.20%

Institutional Holders

6.00

Lipella Pharmaceuticals Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.91%	-	37,074	37,074	100.00%	72,294,000	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	0.32%	0.00%	13,137	13,137	100.00%	25,617,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	2,218	2,218	100.00%	4,000	Mar 31, 2023
UBS GROUP AG	0.02%	-	813	-765	-48.48%	1,585,000	Mar 31, 2023
FMR LLC	0.00%	-	52	52	100.00%	100,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	8	8	100.00%	16,000	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-12,508	-100.00%	-	Mar 31, 2023

Lipella Pharmaceuticals's largest institutional shareholder is VANGUARD GROUP INC, holding 0.91% of the company's total share outstanding, currently valued at $72.29M. The top 10 institutional shareholders own together 1.31% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TWO SIGMA SECURITIES, LLC	0.32%	0.00%	13,137	13,137	100.00%	25,617,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	2,218	2,218	100.00%	4,000	Mar 31, 2023
VANGUARD GROUP INC	0.91%	-	37,074	37,074	100.00%	72,294,000	Mar 31, 2023
UBS GROUP AG	0.02%	-	813	-765	-48.48%	1,585,000	Mar 31, 2023
FMR LLC	0.00%	-	52	52	100.00%	100,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	8	8	100.00%	16,000	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-12,508	-100.00%	-	Mar 31, 2023

The largest Lipella Pharmaceuticals shareholder by % of total assets is TWO SIGMA SECURITIES, LLC. The company owns 13.14K shares of Lipella Pharmaceuticals (LIPO), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.91%	-	37,074	37,074	100.00%	72,294,000	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	0.32%	0.00%	13,137	13,137	100.00%	25,617,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	2,218	2,218	100.00%	4,000	Mar 31, 2023
FMR LLC	0.00%	-	52	52	100.00%	100,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	8	8	100.00%	16,000	Mar 31, 2023
UBS GROUP AG	0.02%	-	813	-765	-48.48%	1,585,000	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-12,508	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Lipella Pharmaceuticals's largest institutional buyer is VANGUARD GROUP INC. The company purchased 37.07K stocks of LIPO, valued at $72.29M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CITADEL ADVISORS LLC	-	-	-	-12,508	-100.00%	-	Mar 31, 2023
UBS GROUP AG	0.02%	-	813	-765	-48.48%	1,585,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	8	8	100.00%	16,000	Mar 31, 2023
FMR LLC	0.00%	-	52	52	100.00%	100,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	2,218	2,218	100.00%	4,000	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	0.32%	0.00%	13,137	13,137	100.00%	25,617,000	Mar 31, 2023
VANGUARD GROUP INC	0.91%	-	37,074	37,074	100.00%	72,294,000	Mar 31, 2023

As of Mar 31 2023, Lipella Pharmaceuticals's biggest institutional seller is CITADEL ADVISORS LLC. The company sold -12.51K shares of LIPO, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.91%	-	37,074	37,074	100.00%	72,294,000	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	0.32%	0.00%	13,137	13,137	100.00%	25,617,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	2,218	2,218	100.00%	4,000	Mar 31, 2023
FMR LLC	0.00%	-	52	52	100.00%	100,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	8	8	100.00%	16,000	Mar 31, 2023

Lipella Pharmaceuticals's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 37.07K shares, valued at $72.29M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CITADEL ADVISORS LLC	-	-	-	-12,508	-100.00%	-	Mar 31, 2023

Lipella Pharmaceuticals's largest sold out institutional shareholder by shares sold is CITADEL ADVISORS LLC, sold -12.51K shares, valued at -, as of undefined.

Lipella Pharmaceuticals Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY CONCORD STREET TRUST	0.00%	41,783	-307	-0.73%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	34,520	-34,520	-50.00%	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	335	-	-	Jan 31, 2024

Lipella Pharmaceuticals's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 41.78K shares, compromising 0.00% of its total assets.

Lipella Pharmaceuticals Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	6	200.00%
31 Dec, 22	2	-

As of 31 Mar 23, 6 institutions are holding Lipella Pharmaceuticals's shares, representing an increase of 200.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	53,302	278.40%
31 Dec, 22	14,086	-

Lipella Pharmaceuticals (LIPO) has 53.30K shares outstanding as of 31 Mar 23, up 278.40% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	1.31%	260.33%
31 Dec, 22	0.36%	-

As of 31 Mar 23, Lipella Pharmaceuticals is held by 1.31% institutional shareholders, representing a 260.33% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	-	-
31 Dec, 22	-	-

- institutional shareholders have increased their position in LIPO stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	1	-
31 Dec, 22	-	-

1 institutional shareholders have reduced their position in LIPO stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	6	200.00%	53,302	278.40%	1.31%	260.33%	-	-	1	-
31 Dec, 22	2	-	14,086	-	0.36%	-	-	-	-	-

Lipella Pharmaceuticals Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 15, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	10,000	$0.76	$7.59K	898,849
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	25,000	$0.87	$21.80K	888,849
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	30,000	$0.79	$23.65K	863,849

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 15, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	10,000	$0.76	$7.59K	898,849
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	25,000	$0.87	$21.80K	888,849
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	30,000	$0.79	$23.65K	863,849

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
May 15, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	10,000	$0.76	$7.59K	898,849
Mar 19, 2024	Pruchnic Ryan	director	-	A-Award	Buy	25,000	$0.77	$19.25K	25,000
Mar 19, 2024	Yoshimura Naoki	director	-	A-Award	Buy	25,000	$0.77	$19.25K	25,000
Mar 19, 2024	Chancellor Michael B	director, 10 percent owner, officer	Chief Medical Officer	A-Award	Buy	80,000	$0.77	$61.60K	80,000
Mar 19, 2024	Birder Lori	director	-	A-Award	Buy	25,000	$0.77	$19.25K	25,000
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	25,000	$0.87	$21.80K	888,849
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	P-Purchase	Buy	30,000	$0.79	$23.65K	863,849
Mar 19, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	A-Award	Buy	80,000	$0.77	$61.60K	80,000
Mar 19, 2024	Johnston Douglas	officer	Chief Financial Officer	A-Award	Buy	50,000	$0.77	$38.50K	50,000
Mar 19, 2024	Cohen Daniel R	director	-	A-Award	Buy	25,000	$0.77	$19.25K	25,000
Mar 19, 2024	Kim Byong	director	-	A-Award	Buy	25,000	$0.77	$19.25K	25,000
Mar 15, 2024	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	A-Award	Buy	144,906	$0.69	$100.00K	833,849
Mar 15, 2024	Chancellor Michael B	director, 10 percent owner, officer	Chief Medical Officer	A-Award	Buy	144,906	$0.69	$100.00K	877,637
Jun 21, 2023	Cohen Daniel R	director	-	A-Award	Buy	25,000	$2.19	$54.75K	25,000
Jun 21, 2023	Battleman David S.	director	-	A-Award	Buy	25,000	$2.19	$54.75K	25,000
Jun 21, 2023	Pruchnic Ryan	director	-	A-Award	Buy	25,000	$2.19	$54.75K	25,000
Jun 21, 2023	Kaufman Jonathan H	director, 10 percent owner, officer	See remarks below.	A-Award	Buy	79,500	$2.19	$174.10K	79,500
Jun 21, 2023	Chancellor Michael B	director, 10 percent owner, officer	Chief Medical Officer	A-Award	Buy	79,500	$2.19	$174.10K	79,500
Jun 21, 2023	Yoshimura Naoki	director	-	A-Award	Buy	25,000	$2.19	$54.75K	25,000
Jun 21, 2023	Kim Byong	director	-	A-Award	Buy	25,000	$2.19	$54.75K	25,000

The last insider buy of LIPO was made by Kaufman Jonathan H on May 15 2024, buying 10,000 shares at $0.76 per share (worth $7.59K).

Lipella Pharmaceuticals Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	1	-	-
Q1 2024	12	-	-
Q2 2023	8	-	-
Q1 2023	-	-	-
Q4 2022	1	4	25.00%
Q1 2022	-	1	-
Q3 2021	-	3	-

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Lipella Pharmaceuticals's insiders, as of Q2 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	1	-	-
Q1 2024	2	-	-
Q2 2023	-	-	-
Q1 2023	-	-	-
Q4 2022	-	-	-
Q1 2022	-	-	-
Q3 2021	-	-	-

As of Q2 2024, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Lipella Pharmaceuticals's stocks.

Lipella Pharmaceuticals Peer Ownership

Ticker	Company
SNTI	Senti Biosciences, Inc.
MNPR	Monopar Therapeutics Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
INBX	Inhibrx, Inc.
FENC	Fennec Pharmaceuticals Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
PTIX	Protagenic Therapeutics, Inc.
ICCC	ImmuCell Corporation
CELC	Celcuity Inc.
MACK	Merrimack Pharmaceuticals, Inc.
ELVN	Enliven Therapeutics, Inc.
ELYM	Eliem Therapeutics, Inc.

LIPO Ownership FAQ

Who Owns Lipella Pharmaceuticals?

Lipella Pharmaceuticals is owned by institutional shareholders (1.31%), insiders (35.49%), and public (63.20%). The largest institutional shareholder of Lipella Pharmaceuticals is VANGUARD GROUP INC (0.91% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

Who are the major institutional shareholders of Lipella Pharmaceuticals?

Lipella Pharmaceuticals's major institutional shareholders are VANGUARD GROUP INC, TWO SIGMA SECURITIES, LLC, TOWER RESEARCH CAPITAL LLC (TRC), UBS GROUP AG, and FMR LLC. The top five shareholders own together 1.31% of the company's share outstanding.

How many Lipella Pharmaceuticals shareholders are there?

As of Mar 2023, there are 6 institutional shareholders of Lipella Pharmaceuticals.

What percentage of Lipella Pharmaceuticals is owned by VANGUARD GROUP INC?

VANGUARD GROUP INC owns 37.07K shares of Lipella Pharmaceuticals, representing 0.91% of the company's total shares outstanding, valued at $72.29M (as of Mar 2023).

What percentage of Lipella Pharmaceuticals is owned by TWO SIGMA SECURITIES, LLC?

As of Mar 2023, TWO SIGMA SECURITIES, LLC holds 13.14K shares of Lipella Pharmaceuticals (LIPO), compromising 0.32% of the company, valued at $25.62M.

What percentage of Lipella Pharmaceuticals is owned by TOWER RESEARCH CAPITAL LLC (TRC)?

TOWER RESEARCH CAPITAL LLC (TRC) is the third largest holder of Lipella Pharmaceuticals. The company owns 2.22K of the company's shares outstanding (worth $4K).